J.D. Finley, Chief Executive Officer, comments on Palisade's recent progress and the potential for PALI-2108 to be the first approved PDE4 inhibitor for #UlcerativeColitis. For recent highlights and upcoming target milestones, visit: https://bit.ly/3M5NX1u
Palisade Bio
Pharmaceutical Manufacturing
Carlsbad, California 1,557 followers
Late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications
About us
Palisade Bio is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibrostenotic Crohn’s Disease.
- Website
-
https://www.palisadebio.com/
External link for Palisade Bio
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Carlsbad, California
- Type
- Privately Held
- Founded
- 2005
- Specialties
- Therapeutics, Drug Development, Gastrobiome, Microbiome, Surgery, Cardiovascular, Gastrointestinal, Biotech, R&D, and COVID-19
Locations
-
Primary
Get directions
7750 El Camino Real
Suite 2A
Carlsbad, California 92008, US
Employees at Palisade Bio
-
Mitchell L. Jones
Transformative research clinician dedicated to revolutionizing patient care for the treatment of serious inflammatory, autoimmune, and fibrotic…
-
William Fairchild
Founding member & Board member at Eppic Medical In
-
J.D. Finley
Chief Executive Officer at Palisade Bio, Inc.
-
Ryker Willie
Senior Vice President, Finance and Corporate Controller at Palisade Bio
Updates
-
Palisade today reported its financial results for the second quarter of 2024 and provided a business update. For details: https://bit.ly/3M5NX1u
-
Based on the modeling and simulations, Palisade has established dose levels and trial design for the Phase 1 clinical study of PALI-2108 for #UlcerativeColitis. The Phase 1 clinical study is on track to commence before year end, learn more: https://bit.ly/3SCaSW3
-
-
Our Chief Medical Officer, Dr. Mitch Jones, highlights the PK modeling and simulations used to establish the Maximum Recommended Starting Dose (MRSD) for Palisade's Phase 1 clinical trial of PALI-2108 for #UlcerativeColitis. For key findings from PK modeling and simulations: https://bit.ly/3SCaSW3
-
Palisade today provided a progress update on the advancement of development for its lead drug candidate, PALI-2108 towards initiation of Phase 1 clinical trials in healthy volunteers and patients with #UlcerativeColitis. For details: https://bit.ly/3SCaSW3
-
-
#ICYMI - Our Chief Medical Officer, Dr. Mitch Jones, highlighted recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108. Watch here: https://bit.ly/4dfWhrc
-
In a "What This Means" segment, Palisade's Chief Medical Officer, Dr. Mitch Jones, discusses the successful completion of a microbiome study confirming bacterial enzymes for local bioactivation of lead product candidate, PALI-2108, and what this means for its planned Phase 1 human clinical study for the treatment of #UlcerativeColitis. Watch it here: https://bit.ly/4dfWhrc
Virtual Investor
virtualinvestorco.com
-
Palisade Bio reposted this
CMO of Palisade Bio, Mitch Jones, MD, PhD, highlights recent findings from a microbiome study and #WhatThisMeans for their lead product, PALI-2108. Watch the full video here: https://lnkd.in/dvPTMXSN #UlcerativeColitis #InflammatoryBowelDisease #IBD #CrohnsDiseaseBio
-
Palisade Bio reposted this
CMO of Palisade Bio, Mitch Jones, MD, PhD, highlights recent findings from a microbiome study and #WhatThisMeans for their lead product, PALI-2108. Watch the full video here: https://lnkd.in/dvPTMXSN #UlcerativeColitis #InflammatoryBowelDisease #IBD #CrohnsDiseaseBio
-
Palisade today announced the release of a Virtual Investor “What This Means” segment. In the segment, Dr. Mitch Jones, CMO of Palisade highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108. For details: https://bit.ly/3A61Wlh
-